FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

The Breakthrough Therapy Designation is based on encouraging results from the Phase 2 TROPiCS-03 study of Trodelvy as a second-line treatment for ES-SCLC.

Trodelvy is currently approved in more than 40 countries for multiple types of breast cancer. The drug is also approved for the treatment of urothelial cancer in many countries.